- The independent Data Safety Monitoring Board (DSMB) has reviewed safety data for the fully enrolled first cohort of ten patients of the Phase 1/2 trial evaluating UniQure NV's QURE AMT-130 for Huntington's disease.
- The DSMB recommended continued dosing in the study. UniQure will now begin to enroll patients in the higher-dose cohort of the trial.
- To date, six patients have been treated with AMT-130, and four patients received imitation surgery.
- The company remains on track to initiate clinical development of AMT-130 in Europe in the second half of 2021 and share initial imaging and biomarker data from the U.S. clinical trial before the end of 2021.
- Price Action: QURE shares are up 2.35% at $34.01 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
